NEW YORK, Sept. 14, 2017 /PRNewswire-USNewswire/ --
Clyde Ishii, MD, President
of The American Society for Aesthetic Plastic
Surgery (ASAPS) announced today significant financial contributions
from breast implant manufacturers Allergan and Sientra, Inc.
(NASDAQ: SIEN) to develop software that will enable ASAPS to
acquire data on the rare condition Breast Implant-Associated
Anaplastic Large Cell Lymphoma (BIA-ALCL). The technology will
enable both the organization and the industry to garner data and
improve outcomes directly at the point-of-care, via ASAPS members'
practices.
BIA-ALCL is a rare spectrum of disorders that can range from a
benign accumulation of fluids around the breast (seroma) to an
extremely rare lymphoma that, when caught early, is readily
curable. It is not a cancer of the breast tissue itself. On a
global scale, approximately 30,000,000 women have breast
implants worldwide, and there have been 12 reported deaths
associated with BIA-ALCL worldwide.
"ASAPS is a leading organization of ABPS board-certified
plastic surgeons specializing in aesthetic procedures of the face
and body. Their objective for patient safety and evidence based
outcomes align perfectly with Sientra's primary mission. We are
proud to fund this technology that will help us better
understand and get to the bottom of this extremely rare condition,"
said Jeffrey M. Nugent, Chairman and
CEO of Sientra. "The promise of point-of-care data will give us new
insights into the cause and prevention of this condition."
"While BIA-ALCL is rare, this alliance with ASAPS to study
BIA-ALCL will enable a broader understanding of the condition vital
to treatment and prevention efforts," explains Gavin Corcoran SVP, Chief Medical Officer of
Allergan. "The correct data points and the right group of surgeons
to collect them from is vital to our understanding of the
condition."
"Our software is able to actually track breast implants or
any other implantable device making it possible to follow the
patient for years to come. The software could easily be used for
any type of Medical Registry, working in conjunction with data that
is currently being collected. It will also be invaluable to our
research efforts via the Aesthetic Surgery Education and Research
Foundation (ASERF), our organization specifically created for
aesthetic research. This would not be possible without the
generous support of Allergan and Sientra," commented Dr.
Ishii. "ASAPS is dedicated to patient safety and quality outcomes,
as well as evidence-based clinical decisions. This initiative and
funding will make a significant difference in our understanding and
continued commitment to our patients."
About ASAPS
The American Society for Aesthetic Plastic Surgery (ASAPS), is
recognized as the world's leading organization devoted entirely to
aesthetic plastic surgery and cosmetic medicine of the face and
body. ASAPS is comprised of over 2,600 Plastic Surgeons;
Active Members are certified by the American Board of Plastic
Surgery (USA) or by the Royal College of Physicians and Surgeons of
Canada and have extensive training in the complete spectrum of
surgical and non-surgical aesthetic procedures. International
Active Members are certified by equivalent boards of their
respective countries. All members worldwide adhere to a strict Code
of Ethics and must meet stringent membership
requirements.
Contact: Leigh Hope
Fountain: 562.799.2356
leigh@surgery.org or sarah@surgery.org
View original
content:http://www.prnewswire.com/news-releases/industry-leaders-allergan-and-sientra-invest-in-the-american-society-for-aesthetic-plastic-surgery-for-breast-implant-research-300519659.html
SOURCE American Society for Aesthetic Plastic Surgery